Reviewing the REPLACE results, I see that Angiomax with Integrilin or ReoPro was superior to heparin (btw, I seem to remember at least one low molecular weight heparin not achieving significant efficacy advantage), but equal without. As such, given the current cost of manufacture -- of all of those -- versus heparin, the total cost study becomes very important. Has management become less vague about when that study would be released? Last I saw was "2003," which is why I put MDCO on the back burner. Unclear whether a positive result from this study would favorably or unfavorably impact Integrilin sales (the immediate reason for my interest). It might help; something to ask the Millenium management at the next opportunity.
Also, there was talk of a different manufacturing process? Is that happening? Seemed as though the margins were thinner than most drugs, due to expense, royalty to BGEN, etc. If all of this is known and anticipated, it would explain the recent strength. Any stumble and it's back to low teens, IMO.
Give me a date on that cost study, and I'll watch.
Cheers, Tuck |
